{"id":"hypidone-hydrochloride-tablets","_chembl":{"chemblId":"CHEMBL1200628","moleculeType":"Small molecule","molecularWeight":"1485.73"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T03:34:27.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122981,"model":"claude-sonnet-4-5-20250929"},"description":"Hypidone Hydrochloride is an investigational small molecule drug developed by Zhejiang Huahai Pharmaceutical Co., Ltd., currently in Phase 2 clinical development. Limited public information is available regarding its molecular target, mechanism of action, and specific therapeutic indications.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT04598607","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects","status":"COMPLETED","sponsor":"Zhejiang Huahai Pharmaceutical Co., Ltd.","startDate":"2020-10-30","conditions":"Major Depressive Disorder","enrollment":36},{"nctId":"NCT03739632","phase":"PHASE2","title":"Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets","status":"COMPLETED","sponsor":"Zhejiang Huahai Pharmaceutical Co., Ltd.","startDate":"2018-11-30","conditions":"Major Depressive Disorder","enrollment":240},{"nctId":"NCT03404466","phase":"PHASE1, PHASE2","title":"To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD","status":"COMPLETED","sponsor":"Zhejiang Huahai Pharmaceutical Co., Ltd.","startDate":"2018-02-24","conditions":"Major Depressive Disorder","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HHT101"],"phase":"phase_2","status":"active","brandName":"Hypidone Hydrochloride tablets","genericName":"Hypidone Hydrochloride tablets","companyName":"Zhejiang Huahai Pharmaceutical Co., Ltd.","companyId":"zhejiang-huahai-pharmaceutical-co-ltd","firstApprovalDate":"","aiSummary":"Hypidone Hydrochloride tablets are used to treat Major Depressive Disorder, as indicated by a clinical study on ClinicalTrials.gov. The mechanism of action of Hypidone Hydrochloride is as a peptidoglycan inhibitor, according to ChEMBL.","enrichmentLevel":2,"visitCount":2,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}